Myelodysplastic Syndromes (MDS)
Poseidon

Click on Product Name for more information
Click on Catalog# for Application Manual

Product Name Color Catalog#
ON= Oncology probes 10 test, ready-to-use format

MDS Related Probes
ON MDS 7q- (7q22; 7q35) red/green KBI-10202
ON MDS 20q- (PTPRT 20q12) / 20q11 red/green KBI-10203
ON EVI t(3;3); inv(3) (3q26) Break red/green KBI-10204
ON EVl t(3;3); inv(3) (3q26) Break, TC red/green/blue KBI-10205
ON MDS 7q- (7q22; 7q35) / SE 7 TC red/green/blue KBI-10207
ON hTERT (5p15) / 5q31 red/green KBI-10208
ON MDS 5q- (5q31; 5q33) red/green KBI-10209
ON MDS 5q- (5q31; 5q33 / hTERT (5p15) TC red/green/blue KBI-10210

 

Poseidon

Click on Product Name for more information
Click on Catalog# for Application Manual

Product Name Color Catalog#
ON= Oncology probes 10 test, ready-to-use format

MDS Related Probes
ON MDS 7q- (7q22; 7q35) red/green KBI-10202
ON MDS 20q- (PTPRT 20q12) / 20q11 red/green KBI-10203
ON EVI t(3;3); inv(3) (3q26) Break red/green KBI-10204
ON EVl t(3;3); inv(3) (3q26) Break, TC red/green/blue KBI-10205
ON MDS 7q- (7q22; 7q35) / SE 7 TC red/green/blue KBI-10207
ON hTERT (5p15) / 5q31 red/green KBI-10208
ON MDS 5q- (5q31; 5q33) red/green KBI-10209
ON MDS 5q- (5q31; 5q33 / hTERT (5p15) TC red/green/blue KBI-10210

 

   
Myelodysplastic Syndromes (MDS) Minimize

The myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic disorders characterized in most patients by peripheral blood cytopenia with hypercellular bone marrow and dysplasia of the cellular elements. Cytogenetic studies play a major role in confirmation of diagnosis and prediction of clinical outcome in MDS, and have contributed to the understanding of its pathogenesis. Clonal chromosomal abnormalities are detected by routine karyotyping techniques in 40%–70% of cases of de novo MDS, and 95% of cases of therapy-related MDS.

The myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic disorders characterized in most patients by peripheral blood cytopenia with hypercellular bone marrow and dysplasia of the cellular elements. Cytogenetic studies play a major role in confirmation of diagnosis and prediction of clinical outcome in MDS, and have contributed to the understanding of its pathogenesis. Clonal chromosomal abnormalities are detected by routine karyotyping techniques in 40%–70% of cases of de novo MDS, and 95% of cases of therapy-related MDS.